SCHEMBL773508

SCHEMBL773508

COCC1CC2C(CCC3C(=O)CCC32)c2ccc(OS(C)(=O)=O)cc21

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.46
ESR2 Q92731 4/20 0.46
STS P08842 14/20 0.35
ABCC4 O15439 1/20 0.34
CYP2C9 P11712 1/20 0.34
ABCC1 P33527 1/20 0.34
SLCO1B1 Q9Y6L6 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
CA9 Q16790 1/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HSD17B1 P14061 1/20 0.32
RECQL P46063 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773507 1.00 ESR1 (0.46) ESR1ESR2STSABCC4CYP2C9
SCHEMBL795934 0.82 ESR1 (0.51) ESR1ESR2HSD17B1
SCHEMBL773302 0.79 STS (0.55) ESR1ESR2STSABCC4CYP2C9
SCHEMBL773301 0.79 STS (0.55) ESR1ESR2STSABCC4CYP2C9
SCHEMBL788040 0.77 STS (0.47) ESR1ESR2STSABCC4CYP2C9
SCHEMBL773716 0.77 ESR1 (0.47) ESR1ESR2STSABCC4CYP2C9
SCHEMBL773715 0.77 ESR1 (0.47) ESR1ESR2STSABCC4CYP2C9
SCHEMBL773717 0.77 ESR1 (0.47) ESR1ESR2STSABCC4CYP2C9
SCHEMBL16176606 0.75 ESR1 (0.36) ESR1ESR2
SCHEMBL16176610 0.75 ESR1 (0.36) ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616477-B1 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS ER-BETA AGONISTS ENDECE LLC (US) 2016-11-09 EP disclosed
US-9422324-B2 6-substituted demethyl-estradiol derivatives as selective ER-β agonists ENDECE LLC (US) 2016-08-23 US disclosed
US-20140315874-A1 6-Substituted Demethyl-Estradiol Derivatives as Selective ER-Beta Agonists ENDECE, LLC 2014-10-23 US disclosed
US-20120071455-A1 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS SELECTIVE ER-BETA AGONISTS ENDECE, LLC 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315874-A1 6-Substituted Demethyl-Estradiol Derivatives as Selective ER-Beta Agonists ESR2, ESR1, ESRRG ESR1 2/4885ESR2 1/4885STS 1219/4885
US-20120071455-A1 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS SELECTIVE ER-BETA AGONISTS ESR2, ESR1, ESRRG ESR1 2/4885ESR2 1/4885STS 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.